These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 24139617)

  • 1. Insights into the mechanism(s) of von Willebrand factor degradation during mechanical circulatory support.
    Bartoli CR; Dassanayaka S; Brittian KR; Luckett A; Sithu S; Siess T; Raess DH; Spence PA; Koenig SC; Dowling RD; D'Souza SE
    J Thorac Cardiovasc Surg; 2014 May; 147(5):1634-43. PubMed ID: 24139617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ADAMTS-13 by Doxycycline Reduces von Willebrand Factor Degradation During Supraphysiological Shear Stress: Therapeutic Implications for Left Ventricular Assist Device-Associated Bleeding.
    Bartoli CR; Kang J; Restle DJ; Zhang DM; Shabahang C; Acker MA; Atluri P
    JACC Heart Fail; 2015 Nov; 3(11):860-9. PubMed ID: 26454844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: mechanical demolition and enzymatic cleavage.
    Bartoli CR; Restle DJ; Zhang DM; Acker MA; Atluri P
    J Thorac Cardiovasc Surg; 2015 Jan; 149(1):281-9. PubMed ID: 25439775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic pathway(s) of acquired von willebrand syndrome with a continuous-flow ventricular assist device: in vitro findings.
    Dassanayaka S; Slaughter MS; Bartoli CR
    ASAIO J; 2013; 59(2):123-9. PubMed ID: 23438773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent.
    Jilma-Stohlawetz P; Quehenberger P; Schima H; Stoiber M; Knöbl P; Steinlechner B; Felli A; Jilma B
    Thromb Res; 2016 Jan; 137():196-201. PubMed ID: 26616301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonphysiologic blood flow triggers endothelial and arterial remodeling in vivo: implications for novel left ventricular assist devices with a peripheral anastomosis.
    Bartoli CR; Spence PA; Siess T; Raess DH; Koenig SC; Dowling RD
    J Thorac Cardiovasc Surg; 2014 Jul; 148(1):311-21. PubMed ID: 24332190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and In Vitro Evidence That Left Ventricular Assist Device-Induced von Willebrand Factor Degradation Alters Angiogenesis.
    Bartoli CR; Zhang DM; Hennessy-Strahs S; Kang J; Restle DJ; Bermudez C; Atluri P; Acker MA
    Circ Heart Fail; 2018 Sep; 11(9):e004638. PubMed ID: 30354363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease.
    Geisen U; Heilmann C; Beyersdorf F; Benk C; Berchtold-Herz M; Schlensak C; Budde U; Zieger B
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):679-84. PubMed ID: 18282712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device.
    Meyer AL; Malehsa D; Bara C; Budde U; Slaughter MS; Haverich A; Strueber M
    Circ Heart Fail; 2010 Nov; 3(6):675-81. PubMed ID: 20739614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II).
    Klovaite J; Gustafsson F; Mortensen SA; Sander K; Nielsen LB
    J Am Coll Cardiol; 2009 Jun; 53(23):2162-7. PubMed ID: 19497443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Models for Translational Investigations of Left Ventricular Assist Device-Associated von Willebrand Factor Degradation.
    Restle DJ; Zhang DM; Hung G; Howard JL; Kallel F; Acker MA; Atluri P; Bartoli CR
    Artif Organs; 2015 Jul; 39(7):569-75. PubMed ID: 25810063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of von Willebrand factor profiles after implantation of left ventricular assist device and total artificial heart.
    Reich HJ; Morgan J; Arabia F; Czer L; Moriguchi J; Ramzy D; Esmailian F; Lam L; Dunhill J; Volod O
    J Thromb Haemost; 2017 Aug; 15(8):1620-1624. PubMed ID: 28586149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased RPM reduces von Willebrand factor degradation with the EVAHEART LVAS: implications for device-specific LVAD management.
    Bartoli CR; Kang J; Motomura T
    J Card Surg; 2020 Jul; 35(7):1477-1483. PubMed ID: 32652785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous-Flow LVAD Support Causes a Distinct Form of Intestinal Angiodysplasia.
    Kang J; Hennessy-Strahs S; Kwiatkowski P; Bermudez CA; Acker MA; Atluri P; McConnell PI; Bartoli CR
    Circ Res; 2017 Sep; 121(8):963-969. PubMed ID: 28729354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of platelet function with light transmission aggregometry in 24 patients supported with a continuous-flow left ventricular assist device: a single-center experience.
    Fiore M; James C; Mouton C; Calderon J; Barandon L; Ouattara A; Picard F
    J Thorac Cardiovasc Surg; 2014 Dec; 148(6):3119-25.e1. PubMed ID: 25212058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device.
    Meyer AL; Malehsa D; Budde U; Bara C; Haverich A; Strueber M
    JACC Heart Fail; 2014 Apr; 2(2):141-5. PubMed ID: 24720921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced continuous-flow left ventricular assist device speed does not decrease von Willebrand factor degradation.
    Kang J; Zhang DM; Restle DJ; Kallel F; Acker MA; Atluri P; Bartoli CR
    J Thorac Cardiovasc Surg; 2016 Jun; 151(6):1747-1754.e1. PubMed ID: 26971377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of a Rotational Speed Modulation System Used With an Implantable Continuous-Flow Left Ventricular Assist Device on von Willebrand Factor Dynamics.
    Naito N; Mizuno T; Nishimura T; Kishimoto S; Takewa Y; Eura Y; Kokame K; Miyata T; Date K; Umeki A; Ando M; Ono M; Tatsumi E
    Artif Organs; 2016 Sep; 40(9):877-83. PubMed ID: 26750507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left Ventricular Assist Device Design Reduces von Willebrand Factor Degradation: A Comparative Study Between the HeartMate II and the EVAHEART Left Ventricular Assist System.
    Bartoli CR; Kang J; Zhang D; Howard J; Acker M; Atluri P; Motomura T
    Ann Thorac Surg; 2017 Apr; 103(4):1239-1244. PubMed ID: 27717422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.
    Rauch A; Legendre P; Christophe OD; Goudemand J; van Belle E; Vincentelli A; Denis CV; Susen S; Lenting PJ
    Thromb Haemost; 2014 Nov; 112(5):1014-23. PubMed ID: 25030452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.